NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab for the treatment of rheumatoid arthritis (review of TA guidance 130, 186, 224, 234 and part review of TA guidance 225 and 247)

Expert statement declaration form

Please sign and return by email to:
Lori.farrar@nice.org.uk

If email is not possible, please return by fax to Lori Farrar, Project Manager on 0161 870 3152
or by post to: NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT

I confirm that:

- I agree with the content of the statement submitted by the British Society of Rheumatology and consequently I will not be submitting a personal statement.

Name: Chris Deighton

Signed: [redacted]

Date: 26.2.13